These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16708075)

  • 21. Assessing p53 in clinical contexts: unlearned lessons and new perspectives.
    Hall PA; McCluggage WG
    J Pathol; 2006 Jan; 208(1):1-6. PubMed ID: 16331594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 and metabolism: Inside the TIGAR.
    Green DR; Chipuk JE
    Cell; 2006 Jul; 126(1):30-2. PubMed ID: 16839873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 Isoform Delta113p53 in zebrafish.
    Chen J; Peng J
    Zebrafish; 2009 Dec; 6(4):389-95. PubMed ID: 19916829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [p53--a key gene for cancer development. Its central significance discloses itself to researchers step by step].
    Janssen K
    Fortschr Med; 1995 Dec; 113(34):48-50. PubMed ID: 8575709
    [No Abstract]   [Full Text] [Related]  

  • 25. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment.
    Harris CC
    Prev Med; 1996; 25(1):10-2. PubMed ID: 8778751
    [No Abstract]   [Full Text] [Related]  

  • 26. The p53 story: layers of complexity.
    Braithwaite AW; Royds JA; Jackson P
    Carcinogenesis; 2005 Jul; 26(7):1161-9. PubMed ID: 15817608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
    Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
    Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
    Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
    Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.
    Konishi H; Karakas B; Abukhdeir AM; Lauring J; Gustin JP; Garay JP; Konishi Y; Gallmeier E; Bachman KE; Park BH
    Cancer Res; 2007 Sep; 67(18):8460-7. PubMed ID: 17875684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of p53 isoforms in renal cell carcinoma.
    Song W; Huo SW; Lü JJ; Liu Z; Fang XL; Jin XB; Yuan MZ
    Chin Med J (Engl); 2009 Apr; 122(8):921-6. PubMed ID: 19493415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer biology: can less be more for p53?
    Berns A
    Nature; 2006 Sep; 443(7108):153-4. PubMed ID: 16971934
    [No Abstract]   [Full Text] [Related]  

  • 32. Functional significance of minor structural and expression changes in stress chaperone mortalin.
    Deocaris CC; Widodo N; Ishii T; Kaul SC; Wadhwa R
    Ann N Y Acad Sci; 2007 Nov; 1119():165-75. PubMed ID: 18056964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Field change, clonality, and early epithelial cancer: possible lessons from p53.
    Ogden GR; Hall PA
    J Pathol; 1997 Feb; 181(2):127-9. PubMed ID: 9120713
    [No Abstract]   [Full Text] [Related]  

  • 34. Cancer biology: sense out of missense.
    Van Dyke T
    Nature; 2005 Mar; 434(7031):287-8. PubMed ID: 15772635
    [No Abstract]   [Full Text] [Related]  

  • 35. Improving cancer therapy through p53 management.
    Haupt S; Haupt Y
    Cell Cycle; 2004 Jul; 3(7):912-6. PubMed ID: 15254405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARC: a potential target for cancer therapy.
    Nikolaev AY; Gu W
    Cell Cycle; 2003; 2(3):169-71. PubMed ID: 12734414
    [No Abstract]   [Full Text] [Related]  

  • 37. Regulation of lipid metabolism by p53 - fighting two villains with one sword.
    Goldstein I; Rotter V
    Trends Endocrinol Metab; 2012 Nov; 23(11):567-75. PubMed ID: 22819212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugging in the absence of p53.
    Aning OA; Cheok CF
    J Mol Cell Biol; 2019 Mar; 11(3):255-264. PubMed ID: 30865230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age activator.
    Novak K
    Nat Rev Cancer; 2002 Feb; 2(2):81. PubMed ID: 12635170
    [No Abstract]   [Full Text] [Related]  

  • 40. STAT3, HIF-1, glucose addiction and Warburg effect.
    Darnell JE
    Aging (Albany NY); 2010 Dec; 2(12):890-1. PubMed ID: 21149895
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.